Search

Your search keyword '"Kang, Y.K."' showing total 178 results
Start Over Author "Kang, Y.K."
178 results on '"Kang, Y.K."'

1. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Azevedo, Sergio, Braghiroli, Maria Ignez, Girotto, Gustavo, Bragagnoli, Arinilda, Branco, Ricardo, Faccio, Adilson, Moretto, Andrea, Skare, Nils, Dutra, Jamille, Viola, Luciana, Vianna, Karina, Meton, Fernando, Sette, Claudia, Faulhaber, Amanda, Tam, Vincent C., Couture, Felix, Biagi, Jim, Castel, Helene, Mulder, Karen, Ko, Yoo-Joung, Zbuk, Kevin, Welch, Stephen, Beaudoin, Annie, Heurgué, Alexandra, Assenat, Eric, Archambeaud, Isabelle, Tougeron, David, Peron, Jean-Marie, Gilabert, Marine, Bronowicki, Jean-Pierre, Cattan, Stephane, Blanc, Jean-Frederic, Bouattour, Mohamed, Phelip, Jean-Marc, Boige, Valerie, Michel, Pierre, Frin, Anne-Claire, De Toni, Enrico N., Berres, Marie-Luise, Vogel, Arndt, Berg, Thomas, Ettrich, Thomas, Waldschmidt, Dirk, Wedemeyer, Hans Heinrich, Worns, Marcus-Alexander, Bitzer, Michael, Weiss, Karl-Heinz, Lau, George, Chan, Stephen L., Yau, Thomas, Tai, Yin Ping, Lee, Ann Shing, Thungappa, Satheesh Chiradoni, N, Lokesh K., Sureshchand Ostwal, Vikas, Ashok, Kattimani Kiran, Mittal, Sushant, Goyal, Hari, Srinivasan, Sankar, Biswas, Ghanashyam, Mohan, Mallavarapu, Limaye, Sewanti, Asarawala, Nirav, Rimassa, Lorenza, Falcone, Alfredo, Gianni, Luca, Gasbarrini, Antonio, Daniele, Bruno, Avallone, Antonio, Paolo Frassineti, Giovanni Luca, Roila, Fausto, Kudo, Masatoshi, Kawaoka, Tomokazu, Morimoto, Manabu, Takikawa, Yasuhiro, Kato, Naoya, Yamashita, Tatsuya, Osaki, Yukio, Motomura, Kenta, Tateishi, Ryosuke, Ohkawa, Kazuyoshi, Wada, Yoshiyuki, Onishi, Hideki, Sasahira, Naoki, Inaba, Yoshitaka, Kurosaki, Masayuki, Tsuji, Kunihiko, Takei, Yoshiyuki, Aramaki, Takeshi, Hagihara, Atsushi, Furuse, Junji, Kioka, Kiyohide, Koga, Hironori, Sasaki, Yutaka, Numata, Kazushi, Tada, Toshifumi, Kawaguchi, Yasunori, Nadano, Seijin, Vasilyev, Alexander, Breder, Valery, Lipatov, Oleg, Dvorkin, Mikhail, Zarubenkov, Oleg, Kutukova, Svetlana, Ponomarev, Roman, Shostka, Kirill, Alyasova, Anna, Topuzov, Eldar, Severtsev, Alexey, Petrov, Yuryi, Erygin, Dmitriy, Berdov, Boris, Kang, Yoon-Koo, Tak, Won-Young, Park, Joong-Won, Lim, Ho Yeong, Heo, Jeong, Kim, Jee Hyun, Kim, Tae-You, Choi, Hye Jin, Varela, María, Reig Monzon, María Elisa, Sangro, Bruno, Martin, Carlos Gómez, Ponce, Carmen Guillén, López, Carlos, Cheng, Ann-Lii, Chao, Yee, Feng, Yin-Hsun, Jeng, Long-Bin, Hung, Chao-Hung, Hou, Ming-Mo, Wang Tsang-En Wang, Jing-Houng, Yen, Chia-Jui, Sukeepaisarnjaroen, Wattana, Sunpaweravong, Patrapim, Charoentum, Chaiyut, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Ungtrakul, Teerapat, Prasongsook, Naiyarat, Maneenil, Kunlatida, Jitpewngarm, Wittawat, Ostapenko, Yurii, Skoryi, Denys, Bondarenko, Igor, Shparyk, Yaroslav, Trukhin, Dmytro, Hotko, Yevhen, Ursol, Grygorii, Kryzhanivska, Anna, Abou-Alfa, Ghassan K., Mody, Kabir, Dayyani, Farshid, Al-Rajabi, Raed, Yarchoan, Mark, Gandhi, Sunil, Crysler, Oxana, He, Aiwu Ruth, Reeves, James, Bahary, Nathan, Mahipal, Amit, Kelley, Robin Kate, Dasgupta, Anirudha, Rowe, Julie, Thota, Ramya, Beg, Muhammad, Morse, Michael, Choi, Sung-hee, Crocenzi, Todd, Somer, Bradley, Abrams, Thomas, Denlinger, Crystal, Zhang, Yue, Sharma, Nisha, Dao, Tu V., Thinh, Nguyen Tien, Tuyet Phuong, Le Thi, Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., Galle, P.R., Rimassa, L., Heurgué, A., Tam, V.C., Van Dao, T., Thungappa, S.C., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Paskow, M.J., Gupta, C., Kurland, J.F., Negro, A., and Abou-Alfa, G.K.

Published
2024
Full Text
View/download PDF

3. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study

Author

Fiocco, M., Dijkstra, P.D.S., Van der Wal, R.J.P., Daolio, P.A., Picci, P., Gronchi, A., Ferrari, S., Özger, H., Maki, R.G., Schreuder, H.W.B., Van der Geest, I.C.M., Bramer, J.A.M., Mastboom, W.J.B., Boffano, M., Goldenitsch, E., Campanacci, D., Cuomo, P., Ferguson, P.C., Griffin, A.M., Sun, Y., Schubert, T., Patel, K., Aranguren, M.S.J., Blancheton, A., Gouin, F., Dürr, H.R., Capellen, C.F., Schwab, J., Iwata, S., Vyrva, O., Weschenfelder, W., Wang, E.H.M., Wook Joo, M., Kang, Y.K., Chung, Y.G., Ebeid, W., Bruns, J., Ueda, T., Mastboom, Monique J L, Palmerini, Emanuela, Verspoor, Floortje G M, Rueten-Budde, Anja J, Stacchiotti, Silvia, Staals, Eric L, Schaap, Gerard R, Jutte, Paul C, Aston, Will, Gelderblom, Hans, Leithner, Andreas, Dammerer, Dietmar, Takeuchi, Akihiko, Thio, Quirina, Niu, Xiaohui, Wunder, Jay S, and van de Sande, Michiel A J

Published
2019
Full Text
View/download PDF

4. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Sangro, B., primary, Chan, S.L., additional, Kelley, R.K., additional, Lau, G., additional, Kudo, M., additional, Sukeepaisarnjaroen, W., additional, Yarchoan, M., additional, De Toni, E.N., additional, Furuse, J., additional, Kang, Y.K., additional, Galle, P.R., additional, Rimassa, L., additional, Heurgué, A., additional, Tam, V.C., additional, Van Dao, T., additional, Thungappa, S.C., additional, Breder, V., additional, Ostapenko, Y., additional, Reig, M., additional, Makowsky, M., additional, Paskow, M.J., additional, Gupta, C., additional, Kurland, J.F., additional, Negro, A., additional, Abou-Alfa, G.K., additional, Azevedo, Sergio, additional, Braghiroli, Maria Ignez, additional, Girotto, Gustavo, additional, Bragagnoli, Arinilda, additional, Branco, Ricardo, additional, Faccio, Adilson, additional, Moretto, Andrea, additional, Skare, Nils, additional, Dutra, Jamille, additional, Viola, Luciana, additional, Vianna, Karina, additional, Meton, Fernando, additional, Sette, Claudia, additional, Faulhaber, Amanda, additional, Tam, Vincent C., additional, Couture, Felix, additional, Biagi, Jim, additional, Castel, Helene, additional, Mulder, Karen, additional, Ko, Yoo-Joung, additional, Zbuk, Kevin, additional, Welch, Stephen, additional, Beaudoin, Annie, additional, Heurgué, Alexandra, additional, Assenat, Eric, additional, Archambeaud, Isabelle, additional, Tougeron, David, additional, Peron, Jean-Marie, additional, Gilabert, Marine, additional, Bronowicki, Jean-Pierre, additional, Cattan, Stephane, additional, Blanc, Jean-Frederic, additional, Bouattour, Mohamed, additional, Phelip, Jean-Marc, additional, Boige, Valerie, additional, Michel, Pierre, additional, Frin, Anne-Claire, additional, Enrico N De Toni, Germany, additional, Berres, Marie-Luise, additional, Vogel, Arndt, additional, Berg, Thomas, additional, Ettrich, Thomas, additional, Waldschmidt, Dirk, additional, Wedemeyer, Hans Heinrich, additional, Worns, Marcus-Alexander, additional, Bitzer, Michael, additional, Weiss, Karl-Heinz, additional, Lau, George, additional, Chan, Stephen L., additional, Yau, Thomas, additional, Tai, Yin Ping, additional, Lee, Ann Shing, additional, Thungappa, Satheesh Chiradoni, additional, N, Lokesh K., additional, Ostwal, Vikas Sureshchand, additional, Ashok, Kattimani Kiran, additional, Mittal, Sushant, additional, Goyal, Hari, additional, Srinivasan, Sankar, additional, Biswas, Ghanashyam, additional, Mohan, Mallavarapu, additional, Limaye, Sewanti, additional, Asarawala, Nirav, additional, Rimassa, Lorenza, additional, Falcone, Alfredo, additional, Gianni, Luca, additional, Gasbarrini, Antonio, additional, Daniele, Bruno, additional, Avallone, Antonio, additional, Paolo Frassineti, Giovanni Luca, additional, Roila, Fausto, additional, Kudo, Masatoshi, additional, Kawaoka, Tomokazu, additional, Morimoto, Manabu, additional, Takikawa, Yasuhiro, additional, Kato, Naoya, additional, Yamashita, Tatsuya, additional, Osaki, Yukio, additional, Motomura, Kenta, additional, Tateishi, Ryosuke, additional, Ohkawa, Kazuyoshi, additional, Wada, Yoshiyuki, additional, Onishi, Hideki, additional, Sasahira, Naoki, additional, Inaba, Yoshitaka, additional, Kurosaki, Masayuki, additional, Tsuji, Kunihiko, additional, Takei, Yoshiyuki, additional, Aramaki, Takeshi, additional, Hagihara, Atsushi, additional, Furuse, Junji, additional, Kioka, Kiyohide, additional, Koga, Hironori, additional, Sasaki, Yutaka, additional, Numata, Kazushi, additional, Tada, Toshifumi, additional, Kawaguchi, Yasunori, additional, Nadano, Seijin, additional, Alexander Vasilyev, Russian Federation, additional, Breder, Valery, additional, Lipatov, Oleg, additional, Dvorkin, Mikhail, additional, Zarubenkov, Oleg, additional, Kutukova, Svetlana, additional, Ponomarev, Roman, additional, Shostka, Kirill, additional, Alyasova, Anna, additional, Topuzov, Eldar, additional, Severtsev, Alexey, additional, Petrov, Yuryi, additional, Erygin, Dmitriy, additional, Berdov, Boris, additional, Kang, Yoon-Koo, additional, Tak, Won-Young, additional, Park, Joong-Won, additional, Lim, Ho Yeong, additional, Heo, Jeong, additional, Kim, Jee Hyun, additional, Kim, Tae-You, additional, Choi, Hye Jin, additional, Varela, María, additional, Reig Monzon, María Elisa, additional, Sangro, Bruno, additional, Martin, Carlos Gómez, additional, Ponce, Carmen Guillén, additional, López, Carlos, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Feng, Yin-Hsun, additional, Jeng, Long-Bin, additional, Hung, Chao-Hung, additional, Hou, Ming-Mo, additional, Wang Tsang-En Wang, Jing-Houng, additional, Yen, Chia-Jui, additional, Sukeepaisarnjaroen, Wattana, additional, Sunpaweravong, Patrapim, additional, Charoentum, Chaiyut, additional, Tanasanvimon, Suebpong, additional, Sirachainan, Ekaphop, additional, Ungtrakul, Teerapat, additional, Prasongsook, Naiyarat, additional, Maneenil, Kunlatida, additional, Jitpewngarm, Wittawat, additional, Ostapenko, Yurii, additional, Skoryi, Denys, additional, Bondarenko, Igor, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Hotko, Yevhen, additional, Ursol, Grygorii, additional, Kryzhanivska, Anna, additional, Abou-Alfa, Ghassan K., additional, Mody, Kabir, additional, Dayyani, Farshid, additional, Al-Rajabi, Raed, additional, Yarchoan, Mark, additional, Gandhi, Sunil, additional, Crysler, Oxana, additional, He, Aiwu Ruth, additional, Reeves, James, additional, Bahary, Nathan, additional, Mahipal, Amit, additional, Kelley, Robin Kate, additional, Dasgupta, Anirudha, additional, Rowe, Julie, additional, Thota, Ramya, additional, Beg, Muhammad, additional, Morse, Michael, additional, Choi, Sung-hee, additional, Crocenzi, Todd, additional, Somer, Bradley, additional, Abrams, Thomas, additional, Denlinger, Crystal, additional, Zhang, Yue, additional, Sharma, Nisha, additional, Dao, Tu V., additional, Thinh, Nguyen Tien, additional, and Tuyet Phuong, Le Thi, additional

Published
2024
Full Text
View/download PDF

5. The Protein Folding Problem

Author

Scheraga, H. A., Liwo, A., Oldziej, S., Czaplewski, C., Pillardy, J., Lee, J., Ripoll, D.R., Vila, J.A., Kazmierkiewicz, R., Saunders, J.A., Arnautova, Y.A., Gibson, K.D., Jagielska, A., Khalili, M., Chinchio, M., Nanias, M., Kang, Y.K., Schafroth, H., Ghosh, A., Elber, R., Makowski, M., Barth, Timothy J., editor, Griebel, Michael, editor, Keyes, David E., editor, Nieminen, Risto M., editor, Roose, Dirk, editor, Schlick, Tamar, editor, Leimkuhler, Benedict, editor, Chipot, Christophe, editor, Elber, Ron, editor, Laaksonen, Aatto, editor, Mark, Alan, editor, Schütte, Christoph, editor, and Skeel, Robert, editor

Published
2006
Full Text
View/download PDF

10. 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors

Author

Sharma, M.R., primary, Carvajal, R.D., additional, Hanna, G.J., additional, Kang, Y.K., additional, Lee, J., additional, Lee, K.W., additional, Li, B.T., additional, Moore, K.N., additional, Pegram, M., additional, Rasco, D., additional, Spira, A., additional, Wang, D., additional, Weinberg, B.A., additional, Alonso, M., additional, Fang, L., additional, Husain, A., additional, Kowanetz, M., additional, Perez, E.A., additional, and Dumbrava, E.I., additional

Published
2021
Full Text
View/download PDF

13. Physics-based protein-structure prediction using a hierarchical protocol based on the UNRES force field: assessment in two blind tests

Author

Oldziej, S., Czaplewski, C., Liwo, A., Chinchio, M., Nanias, M., Vila, J.A., Khalili, M., Arnautova, Y.A., Jagielska, A., Makowski, M., Schafroth, H.D., Kazmierkiewicz, R., Ripoll, D.R., Pillardy, J., Saunders, J.A., Kang, Y.K., Gibson, K.D., and Scheraga, H.A.

Subjects
Protein biosynthesis -- Methods, Proteins -- Structure, Proteins -- Research, Science and technology
Abstract

Recent improvements in the protein-structure prediction method developed in our laboratory, based on the thermodynamic hypothesis, are described. The conformational space is searched extensively at the united-residue level by using our physics-based UNRES energy function and the conformational space annealing method of global optimization. The lowest-energy coarse-grained structures are then converted to an all-atom representation and energy-minimized with the ECEPP/3 force field. The procedure was assessed in two recent blind tests of protein-structure prediction. During the first blind test, we predicted large fragments of [alpha] and [alpha]+[beta] proteins [60-70 residues with [C.sup.[alpha]] rms deviation (rmsd) global optimization | thermodynamic hypothesis

Published
2005

14. EORTC-1203-GITCG - the 'INNOVATION'-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Author

Wagner, A.D., Grabsch, H.I., Mauer, M., Marreaud, S., Caballero, C., Thuss-Patience, P., Mueller, L., Elme, A., Moehler, M.H., Martens, U., Kang, Y.K., Rha, S.Y., Cats, A., Tokunaga, M., and Lordick, F.

Subjects
Gastric cancer, Gastro-esophageal junction cancer, HER2, Perioperative chemotherapy, Pertuzumab, Trastuzumab
Abstract

10-20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined. Two hundred and-fifteen patients from 52 sites in 14 countries will be centrally randomized (1:2:2 ratio) to one of the following treatment arms: 1. Standard: CT alone. CT regimens will be FLOT (5-FU, leucovorin, oxaliplatin, taxotere) CapOx (capecitabine, oxaliplatin) or FOLFOX (5-FU, leucovorin, oxaliplatin) according to investigator's choice in Europe, and cisplatin/capecitabine in Asia. 2. Experimental arm 1: CT as in control group, plus T (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) at day 1, independent of CT chosen for 3 cycles of 3 weeks before and after surgery. 3. Experimental arm 2: CT plus T as in experimental arm 1, plus P (840 mg every 3 weeks) on day 1. Adjuvant treatment with T or T + P will continue for 17 cycles in total. Stratification factors are: histology (intestinal/non-intestinal); region (Asia vs Europe); location (GEJ vs non-GEJ); HER2 immunohistochemistry score (IHC 3+ vs IHC 2+/FISH+) and chemotherapy regimen. Primary objective is to detect an increase in the major pathological response rate from 25 to 45% either with CT plus T alone, or with CT plus the combination of T and P. Depending on the results of the INNOVATION trial, the addition of HER2 targeted treatment with either T or T and P to CT may inform future study designs or become a standard in the perioperative management HER2+ GC. This article reports a health care intervention on human participants and was registered on July 10, 2014 under ClinicalTrials.gov identifier: NCT02205047 ; EudraCT: 2014-000722-38.

Published
2019

15. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Author

Demetri, G.D., Antonescu, C.R., Bjerkehagen, B., Bovée, J., Boye, K., Chacón, M., Tos, A.P. Dei, Desai, J., Fletcher, J.A., Gelderblom, H., George, S., Gronchi, A., Haas, R.L.M., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Judson, I., Kang, Y.K., Kawai, A., Lazar, A.J., Cesne, A. Le, Maestro, R., Maki, R.G., Martín, J., Patel, S, Penault-Llorca, F., Raut, C.P., Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I.M., Shen, L., Serrano, C., Schöffski, P, Stacchiotti, S., Hall, K.S., Tap, W.D., Thomas, D.M., Trent, J., Valverde, C., Graaf, W.T.A. van der, Mehren, M. von, Wagner, A., Wardelmann, E., Naito, Y., Zalcberg, J., Blay, J.Y., Demetri, G.D., Antonescu, C.R., Bjerkehagen, B., Bovée, J., Boye, K., Chacón, M., Tos, A.P. Dei, Desai, J., Fletcher, J.A., Gelderblom, H., George, S., Gronchi, A., Haas, R.L.M., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Judson, I., Kang, Y.K., Kawai, A., Lazar, A.J., Cesne, A. Le, Maestro, R., Maki, R.G., Martín, J., Patel, S, Penault-Llorca, F., Raut, C.P., Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I.M., Shen, L., Serrano, C., Schöffski, P, Stacchiotti, S., Hall, K.S., Tap, W.D., Thomas, D.M., Trent, J., Valverde, C., Graaf, W.T.A. van der, Mehren, M. von, Wagner, A., Wardelmann, E., Naito, Y., Zalcberg, J., and Blay, J.Y.

Abstract

Contains fulltext : 230129.pdf (Publisher’s version ) (Open Access), Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raises a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists, and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.

Published
2020

18. Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints

Author

Mastboom, M.J.L., Staals, E.L., Verspoor, F.G.M., Rueten-Budde, A.J., Stacchiotti, S., Palmerini, E., Schaap, G.R., Jutte, P.C., Aston, W., Leithner, A., Dammerer, D., Takeuchi, A., Thio, Q., Niu, X., Wunder, J.S., Sande, M.A.J. van de, Fiocco, M., Dijkstra, P.D.S., Wal, R.J.P. van der, Daolio, P.A., Picci, P., Gronchi, A., Ferrari, S., Ozger, H., Maki, R.G., Schreuder, H.W.B., Geest, I.C.M. van der, Bramer, J.A.M., Mastboom, W.J.B., Boffano, M., Goldenitsch, E., Companacci, D., Cuomo, P., Ferguson, P.C., Griffin, A.M., Sun, Y., Schubert, T., Patel, K., Aranguren, M.S.J., Blancheton, A., Gouin, F., Durr, H.R., Capellen, C.F., Schwab, J., Iwata, S., Vyrva, O., Weschenfelder, W., Wang, E.H.M., Joo, M.W., Kang, Y.K., Chung, Y.G., Ebeid, W., Bruns, J., Ueda, T., and TGCT Study Grp

Subjects
Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]
Abstract

Contains fulltext : 208133.pdf (Publisher’s version ) (Closed access) Background: Localized-type tenosynovial giant cell tumor (TGCT) is a rare, neoplastic disease with only limited data supporting treatment protocols. We describe treatment protocols and evaluate their oncological outcome, complications, and functional results in a large multicenter cohort of patients. A secondary study aim was to identify factors associated with local recurrence after surgical treatment. Methods: Patients with histologically proven localized TGCT of a large joint were included if they had been treated between 1990 and 2017 in 1 of 31 tertiary sarcoma centers. Of 941 patients with localized TGCT, 62% were female. The median age at initial treatment was 39 years, and the median duration of follow-up was 34 months. Sixty-seven percent of the tumors affected the knee, and the primary treatment at the tertiary center was 1-stage open resection in 73% of the patients. Proposed factors for predicting a first local recurrence after treatment in the tertiary center were tested in a univariate analysis, and those that demonstrated significance were subsequently included in a multivariate analysis. Results: The localized TGCT recurred in 12% of all cases, with local-recurrence-free rates at 3, 5, and 10 years of 88%, 83%, and 79%, respectively. The strongest factor for predicting recurrent disease was a prior recurrence (p < 0.001). Surgical treatment decreased pain and swelling in 71% and 85% of the patients, respectively, and such treatment was associated with complications in 4% of the patients. Univariate and multivariate analyses of the patients who had not undergone therapy previously yielded positive associations between local recurrence and a tumor size of >= 5 cm versus

Published
2019

19. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study

Author

Mastboom, Monique J L, primary, Palmerini, Emanuela, additional, Verspoor, Floortje G M, additional, Rueten-Budde, Anja J, additional, Stacchiotti, Silvia, additional, Staals, Eric L, additional, Schaap, Gerard R, additional, Jutte, Paul C, additional, Aston, Will, additional, Gelderblom, Hans, additional, Leithner, Andreas, additional, Dammerer, Dietmar, additional, Takeuchi, Akihiko, additional, Thio, Quirina, additional, Niu, Xiaohui, additional, Wunder, Jay S, additional, van de Sande, Michiel A J, additional, Fiocco, M., additional, Dijkstra, P.D.S., additional, Van der Wal, R.J.P., additional, Daolio, P.A., additional, Picci, P., additional, Gronchi, A., additional, Ferrari, S., additional, Özger, H., additional, Maki, R.G., additional, Schreuder, H.W.B., additional, Van der Geest, I.C.M., additional, Bramer, J.A.M., additional, Mastboom, W.J.B., additional, Boffano, M., additional, Goldenitsch, E., additional, Campanacci, D., additional, Cuomo, P., additional, Ferguson, P.C., additional, Griffin, A.M., additional, Sun, Y., additional, Schubert, T., additional, Patel, K., additional, Aranguren, M.S.J., additional, Blancheton, A., additional, Gouin, F., additional, Dürr, H.R., additional, Capellen, C.F., additional, Schwab, J., additional, Iwata, S., additional, Vyrva, O., additional, Weschenfelder, W., additional, Wang, E.H.M., additional, Wook Joo, M., additional, Kang, Y.K., additional, Chung, Y.G., additional, Ebeid, W., additional, Bruns, J., additional, and Ueda, T., additional

Published
2019
Full Text
View/download PDF

24. First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

Author

Gazzah, A., primary, Stjepanovic, N., additional, Ryu, M.H., additional, Tabernero, J., additional, Soria, J.C., additional, Bedard, P., additional, Kang, Y.K., additional, Bahleda, R., additional, Guillemin-Paveau, H., additional, Henry, C., additional, Hatteville, L., additional, Zilocchi, C., additional, Demers, B., additional, and Hierro, C., additional

Published
2016
Full Text
View/download PDF

25. 64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047

Author

Wagner, A.D., primary, Kang, Y.K., additional, Van Dieren, J., additional, Mauer, M., additional, Grabsch, H., additional, Caballero, C., additional, Kataoka, K., additional, Atasoy, A., additional, Cho, J.Y., additional, Mohler, M., additional, Roth, A., additional, Salto-Tellez, M., additional, Langer, R., additional, Schuhmacher, C., additional, Van Sandick, J., additional, Van Grieken, N., additional, and Lordick, F., additional

Published
2016
Full Text
View/download PDF

26. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Author

Demetri, G.D., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., Mehren, M. von, Joensuu, H., Badalamenti, G., Blackstein, M., Cesne, A. le, Schoffski, P., Maki, R.G., Bauer, S., Nguyen, B.B., Xu, J., Nishida, T., Chung, J., Kappeler, C., Kuss, I., Laurent, D., Casali, P.G., Graaf, W.T.A. van der, Demetri, GD, Reichardt, P, Kang, YK, Blay, JY, Rutkowski, P, Gelderblom, H, Hohenberger, P, Leahy, M, von Mehren, M, Joensuu, H, Badalamenti, G, Blackstein, M, Le Cesne, A, Schöffski, P, Maki, RG, Bauer, S, Nguyen, BB, Xu, J, Nishida, T, Chung, J, Kappeler, C, Kuss, I, Laurent, D, Casali, PG, Demetri, Gd, Kang, Yk, Blay, Jy, Maki, Rg, Nguyen, Bb, Casali, Pg, Biasco, G, and study investigators, Grid

Subjects
Oncology, Male, Indoles, Pyridines, Settore MED/06 - Oncologia Medica, SU11248, Medizin, Piperazines, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Clinical endpoint, Sunitinib, Treatment Failure, regorafenib, gastrointestinal stromal tumours, imatinib and sunitinib, Gastrointestinal Neoplasms, education.field_of_study, GiST, KIT, Age-related aspects of cancer Quality of hospital and integrated care [ONCOL 2], General Medicine, Middle Aged, Survival Rate, Benzamides, Imatinib Mesylate, Female, ADJUVANT IMATINIB, TYROSINE KINASE INHIBITOR, Colorectal Neoplasms, Life Sciences & Biomedicine, medicine.drug, GROWTH-FACTOR, medicine.medical_specialty, Gastrointestinal Stromal Tumors, Population, MESYLATE, Antineoplastic Agents, IMATINIB, Article, MECHANISMS, Medicine, General & Internal, Double-Blind Method, Translational research [ONCOL 3], General & Internal Medicine, Regorafenib, Internal medicine, MANAGEMENT, medicine, Humans, Pyrroles, education, Protein Kinase Inhibitors, Aged, Science & Technology, GASTROINTESTINAL STROMAL TUMOURS, MUTATIONS, business.industry, Phenylurea Compounds, GIST, regorafenib, imatinib, sunitinib, phase III trial, Surgery, Clinical trial, Imatinib mesylate, Pyrimidines, chemistry, business, RESISTANCE
Abstract

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geographical region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 weeks of each 4 week cycle. The study sponsor, participants, and investigators were masked to treatment assignment. The primary endpoint was progression-free survival (PFS). At disease progression, patients assigned placebo could crossover to open-label regorafenib. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01271712. RESULTS: From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66). Data cutoff was Jan 26, 2012. Median PFS per independent blinded central review was 4.8 months (IQR 1.4-9.2) for regorafenib and 0.9 months (0.9-1.8) for placebo (hazard ratio [HR] 0.27, 95% CI 0.19-0.39; p

Published
2013

27. Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST

Author

Demetri, G.D., Jeffers, M., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., Mehren, M. von, Joensuu, H., Badalamenti, G., Blackstein, M., Cesne, A. le, Schoffski, P., Maki, R.G., Bauer, S., Nguyen, B.B., Xu, J.M., Nishida, T., Chung, J., Lathia, C.D., Kappeler, C., Kuss, I., Laurent, D., and Casali, P.G.

Subjects
Medizin
Published
2013

32. 2307 Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis

Author

Kim, J.H., primary, Park, S.R., additional, Ryu, M.H., additional, Ryoo, B.Y., additional, Kim, K.P., additional, Su Kim, Beom, additional, Yoo, M.W., additional, Yook, J.H., additional, Sik Kim, Byung, additional, and Kang, Y.K., additional

Published
2015
Full Text
View/download PDF

33. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Author

Van Cutsem, E., Dicato, M., Geva, R., Arber, N., Bang, Y., Benson, A., Cervantes, A., Diaz-Rubio, E., Ducreux, M., Glynne-Jones, R., Grothey, A., Haller, D., Haustermans, K., Kerr, D., Nordlinger, B., Marshall, J., Minsky, B.D., Kang, Y.K., Labianca, R., Lordick, F., Ohtsu, A., Pavlidis, N., Roth, A., Rougier, P., Schmoll, H.J., Sobrero, A., Tabernero, J., Van de Velde, C., and Zalcberg, J.

Published
2011
Full Text
View/download PDF

34. The Protein Folding Problem

Author

Scheraga, H. A., primary, Liwo, A., additional, Oldziej, S., additional, Czaplewski, C., additional, Pillardy, J., additional, Lee, J., additional, Ripoll, D.R., additional, Vila, J.A., additional, Kazmierkiewicz, R., additional, Saunders, J.A., additional, Arnautova, Y.A., additional, Gibson, K.D., additional, Jagielska, A., additional, Khalili, M., additional, Chinchio, M., additional, Nanias, M., additional, Kang, Y.K., additional, Schafroth, H., additional, Ghosh, A., additional, Elber, R., additional, and Makowski, M., additional

Full Text
View/download PDF

35. 501 Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinical activity of AZD9150, a therapeutic STAT3 ASO

Author

McCoon, P., primary, Woessner, R., additional, DuPont, R., additional, Bell, K., additional, Collins, M., additional, Pablo, L., additional, Lawson, D., additional, Nadella, P., additional, Jacobs, V., additional, Womack, C., additional, Reimer, C., additional, Hong, D., additional, Nemunaitis, J., additional, Kang, Y.K., additional, Kim, T.Y., additional, Lim, H.Y., additional, Okusaka, T., additional, Nadano, S., additional, Lin, C.C., additional, and Lyne, P., additional

Published
2014
Full Text
View/download PDF

36. 217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

Author

Kang, Y.K., primary, Ryoo, B.Y., additional, Kim, T.Y., additional, Lee, K.H., additional, Lim, H.Y., additional, Lee, S.J., additional, Ikeda, M., additional, Okusaka, T., additional, Nadano, S., additional, Lin, C.C., additional, Poon, T.P., additional, Yen, C.J., additional, McCoon, P., additional, Neumann, F., additional, Vishwantahan, K., additional, DuPont, R., additional, and Lyne, P., additional

Published
2014
Full Text
View/download PDF

38. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Author

Finn, R.S., Poon, R.T., Yau, T., Klumpen, H.J., Chen, L.T., Kang, Y.K., Kim, T.Y., Gomez-Martin, C., Rodriguez-Lope, C., Kunz, T., Paquet, T., Brandt, U., Sellami, D., Bruix, J., Finn, R.S., Poon, R.T., Yau, T., Klumpen, H.J., Chen, L.T., Kang, Y.K., Kim, T.Y., Gomez-Martin, C., Rodriguez-Lope, C., Kunz, T., Paquet, T., Brandt, U., Sellami, D., and Bruix, J.

Abstract

1 december 2013, Item does not contain fulltext, BACKGROUND & AIMS: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). Combination therapy targeting multiple signaling pathways may improve outcomes. This phase I study was designed to determine the maximum tolerated dose (MTD) of everolimus given with sorafenib 400mg twice daily in patients with advanced HCC of Child-Pugh class A liver function who were naive to systemic therapy. METHODS: Everolimus was initiated at 2.5mg once daily and increased per a Bayesian sequential dose-escalation scheme based on the dose-limiting toxicities experienced within the first 28days of treatment. Adverse events were assessed continuously. Efficacy was evaluated using the best overall response rate per RECIST. RESULTS: Thirty patients were enrolled; 25 were evaluable for MTD determination. One out of 12 patients treated with everolimus 2.5mg once daily and 6 out of 13 patients treated with everolimus 5.0mg once daily experienced a dose-limiting toxicity, most commonly thrombocytopenia (n=5). All patients experienced 1 adverse event, most commonly diarrhea (66.7%), hand-foot skin reaction (66.7%), and thrombocytopenia (50.0%). Best overall response was stable disease (62.5% and 42.9% in the 2.5-mg and 5.0-mg cohorts, respectively). Median time to progression and overall survival in the 2.5-mg cohort were 4.5months and 7.4months, respectively, and 1.8months and 11.7months, respectively, in the 5.0-mg cohort. CONCLUSIONS: In patients with advanced HCC, the everolimus MTD in combination with standard-dose sorafenib was 2.5mg once daily. The inability to achieve a biologically effective everolimus concentration at the MTD precluded phase II study of this combination.

Published
2013

46. 6156 POSTER Noninvasive Measurements From Computed Tomography and Laboratory Results Predict Hepatic Sinusoidal Injury Associated With Oxaliplatin-based Chemotherapy in Patients With Metastatic Colorectal Cancer

Author

Hong, Y.S., primary, Kim, D.Y., additional, Park, S.H., additional, Kim, K.P., additional, Lee, J.L., additional, Ryu, M.H., additional, Chang, H.M., additional, Ryoo, B.Y., additional, Kang, Y.K., additional, and Kim, T.W., additional

Published
2011
Full Text
View/download PDF

47. 3032 POSTER Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels – Exploratory Analysis of the Phase III ToGA Study

Author

Shen, L., primary, Kang, Y.K., additional, Lichinitser, M., additional, Chung, H.C., additional, Ohtsu, A., additional, Bang, Y.J., additional, Van Cutsem, E., additional, Al-Sakaff, N., additional, Hill, J., additional, and Sawaki, A., additional

Published
2011
Full Text
View/download PDF

50. 6570 POSTER Update of AMC 0201 Study – a Randomized Phase III Trial Comparing Mitomycin-C Plus Short-term Doxifluridine (Mf) Versus Mitomycin-C Plus Long-term Doxifluridine Plus Cisplatin (MFP) After Curative Resection of Advanced Gastric Cancer (NCT00296335)

Author

Min, Y.J., primary, Kang, Y.K., additional, Ryoo, B.Y., additional, Zang, D.Y., additional, Kim, G.Y., additional, Yang, D.H., additional, Jang, S.J., additional, Yook, J.H., additional, Oh, S.T., additional, and Kim, B.S., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results